OncoCyte Corporation (OCX) Price-to-Projected Revenue Ratio

Public company logo of OncoCyte Corporation (OCX)

OncoCyte Corporation (OCX) is implementing advanced liquid biopsy for the early detection of tumors in the blood. Current revenue is based on the sale of DetermaRx tests, which determine the risk of disease recurrence. The projected P/S ratio visualizes market revenue expectations, where the value 24.00 represents the most recent figure. Strong pricing power in oncology diagnostics and inelastic physician demand confirm the uniqueness of the company's predictive methods.

OCX OncoCyte: Market Cap to Future Revenue Ratio in the range 07/04/2022 - 06/18/2025

Summary analytical data breakdowns for OncoCyte Inc (OCX)

- current price and projected stock value:
Stock Price OncoCyte|OCX - Analyst Median Target
- market capitalization details:
Market Value OncoCyte Inc|OCX - Company Buyout Price
- book value of equity indicators:
Net Assets per Single Share OncoCyte|OCX - Total Stockholders' Equity|Market Value to Book Value Ratio oncocyte.com|OCX - Total Business Assets
- company liabilities and liquidity data:
Total Debt to Capital OncoCyte Corporation|OCX - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity OncoCyte Corporation|OCX - Company Cumulative Debt|Debts to Book Capitalization OncoCyte Inc|OCX - Company Long-Term Liabilities|Company Current Liabilities OncoCyte|Quick Liquidity Indicator oncocyte.com
- business earnings and investment ratios data:
OCX - Profit After Payment of Taxes|Projected Future Earnings OncoCyte Corporation|OCX - Market Cap to Earnings|Projected Price to Earnings OncoCyte Corp.|OCX - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple OncoCyte Inc|OCX - Operating profit before deduction of amortization|Earnings per share for the last twelve months OncoCyte|OCX - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months oncocyte.com|OCX - Earnings per share increase in current year|Net earnings per share growth forecast for next year OncoCyte Corporation
- revenue and sales details:
OCX - Company Annual Revenue|Company Projected Revenue OncoCyte|OCX - Price to Sales|Price-to-Projected Revenue Ratio OncoCyte Inc
Initial company analysis:OncoCyte OCX
Product sample of OncoCyte Corporation

For an investor assessing the financial stability of an issuer, the forward P/S ratio serves as a measure of the business's market value relative to projected revenue, allowing for the determination of the premium paid for every dollar of expected sales. In the context of OncoCyte Corporation (OCX), this chart reflects the efficiency of monetizing oncology tests through network partners, helping to align current capitalization with the potential for organic revenue growth following restructuring.

Competitors of OncoCyte Corporation (OCX)

Forward P/S Multiple CAI (Caris Life Sciences)|Market Cap to Expected Sales Ratio Guardant Health Inc (GH)|VCYT - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Celcuity Therapeutics CELC|GRAIL, Inc. (GRAL) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio myriad.com (MYGN)|Price-to-Projected Revenue Ratio Castle Biosciences, Inc.|Market Cap to Projected Revenue BNR (Burning Rock Biotech Limited)|Forward P/S Multiple VNRX|Forward Price-to-Revenue Multiple Biodesix Corporation BDSX|Price-to-Projected Revenue Ratio Precipio, Inc. PRPO|Check-Cap Ltd (CHEK) - Market Cap to Future Revenue Ratio|Mainz Biomed N.V. - Forward P/S Multiple